BACKGROUND/AIMS: Hepatocellular carcinoma (HCC) has the most rapidly rising cancer incidence in the US and Europe. The KLF6 tumor suppressor is frequently inactivated in HCC by loss-of-heterozygosity (LOH) and/or mutation. METHODS: Here we have analyzed 33 HBV- and 40 HCV-related HCCs for mRNA expression of wildtype KLF6 (wtKLF6) as well as the KLF6 variant 1 (SV1), a truncated, growth-promoting variant that antagonizes wtKLF6 function. The HCV-related tumors analyzed represented the full histologic spectrum from cirrhosis and dysplasia to metastatic cancer. RESULTS: Expression of KLF6 mRNA is decreased in 73% of HBV-associated HCCs compared to matched surrounding tissue (ST), with reductions of approximately 80% in one-third of the patients. KLF6 mRNA expression is also reduced in dysplastic nodules from patients with HCV compared to cirrhotic livers (p<0.005), with an additional, marked decrease in the very advanced, metastatic stage (p<0.05). An increased ratio of KLF6SV1/wt KLF6 is present in a subset (6/33, 18%) of the HBV-related HCCs compared to matched ST. Reconstituting KLF6 in HepG2 cells by retroviral infection decreased proliferation and related markers including cyclin D1 and beta-catenin, increased cellular differentiation based on induction of albumin, E-cadherin, and decreased alpha fetoprotein. CONCLUSIONS: We conclude that reduced KLF6 expression is common in both HBV- and HCV-related HCCs and occurs at critical stages during cancer progression. Effects of KLF6 are attributable to regulation of genes controlling hepatocyte growth and differentiation.
BACKGROUND/AIMS: Hepatocellular carcinoma (HCC) has the most rapidly rising cancer incidence in the US and Europe. The KLF6tumor suppressor is frequently inactivated in HCC by loss-of-heterozygosity (LOH) and/or mutation. METHODS: Here we have analyzed 33 HBV- and 40 HCV-related HCCs for mRNA expression of wildtype KLF6 (wtKLF6) as well as the KLF6 variant 1 (SV1), a truncated, growth-promoting variant that antagonizes wtKLF6 function. The HCV-related tumors analyzed represented the full histologic spectrum from cirrhosis and dysplasia to metastatic cancer. RESULTS: Expression of KLF6 mRNA is decreased in 73% of HBV-associated HCCs compared to matched surrounding tissue (ST), with reductions of approximately 80% in one-third of the patients. KLF6 mRNA expression is also reduced in dysplastic nodules from patients with HCV compared to cirrhotic livers (p<0.005), with an additional, marked decrease in the very advanced, metastatic stage (p<0.05). An increased ratio of KLF6SV1/wt KLF6 is present in a subset (6/33, 18%) of the HBV-related HCCs compared to matched ST. Reconstituting KLF6 in HepG2 cells by retroviral infection decreased proliferation and related markers including cyclin D1 and beta-catenin, increased cellular differentiation based on induction of albumin, E-cadherin, and decreased alpha fetoprotein. CONCLUSIONS: We conclude that reduced KLF6 expression is common in both HBV- and HCV-related HCCs and occurs at critical stages during cancer progression. Effects of KLF6 are attributable to regulation of genes controlling hepatocyte growth and differentiation.
Authors: Goutham Narla; Analisa DiFeo; Shen Yao; Asoka Banno; Eldad Hod; Helen L Reeves; Rui F Qiao; Olga Camacho-Vanegas; Alice Levine; Alexander Kirschenbaum; Andrew M Chan; Scott L Friedman; John A Martignetti Journal: Cancer Res Date: 2005-07-01 Impact factor: 12.701
Authors: Analisa DiFeo; Goutham Narla; Jennifer Hirshfeld; Olga Camacho-Vanegas; Jyothsna Narla; Stephen L Rose; Tamara Kalir; Shen Yao; Alice Levine; Michael J Birrer; Tomas Bonome; Scott L Friedman; Richard E Buller; John A Martignetti Journal: Clin Cancer Res Date: 2006-06-15 Impact factor: 12.531
Authors: A DiFeo; G Narla; O Camacho-Vanegas; H Nishio; S L Rose; R E Buller; S L Friedman; M J Walsh; J A Martignetti Journal: Oncogene Date: 2006-05-15 Impact factor: 9.867
Authors: T Masuda; H Saito; F Kaneko; K Atsukawa; M Morita; H Inagaki; N Kumagai; K Tsuchimoto; A H Ishii Journal: In Vitro Cell Dev Biol Anim Date: 2000-06 Impact factor: 2.416
Authors: Dan Li; Steven Yea; Side Li; Zhu Chen; Goutham Narla; Michaela Banck; Jorge Laborda; Song Tan; Jeffrey M Friedman; Scott L Friedman; Martin J Walsh Journal: J Biol Chem Date: 2005-05-25 Impact factor: 5.157
Authors: Nobuyuki Matsumoto; Atsushi Kubo; Huixian Liu; Kuniharu Akita; Friedrich Laub; Francesco Ramirez; Gordon Keller; Scott L Friedman Journal: Blood Date: 2005-10-18 Impact factor: 22.113
Authors: Fabio Farinati; Dario Marino; Massimo De Giorgio; Anna Baldan; Maria Cantarini; Carmela Cursaro; Gianludovico Rapaccini; Paolo Del Poggio; Maria Anna Di Nolfo; Luisa Benvegnù; Marco Zoli; Franco Borzio; Mauro Bernardi; Franco Trevisani Journal: Am J Gastroenterol Date: 2006-03 Impact factor: 10.864
Authors: Diana Vetter; Michal Cohen-Naftaly; Augusto Villanueva; Youngmin A Lee; Peri Kocabayoglu; Rebekka Hannivoort; Goutham Narla; Josep M Llovet; Swan N Thung; Scott L Friedman Journal: Hepatology Date: 2012-08-27 Impact factor: 17.425
Authors: Luisa M Botella; Francisco Sanz-Rodriguez; Yusuke Komi; Africa Fernandez-L; Elisa Varela; Eva M Garrido-Martin; Goutham Narla; Scott L Friedman; Soichi Kojima Journal: Biochem J Date: 2009-04-15 Impact factor: 3.857